{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:37:21Z","timestamp":1777351041782,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Ministry of Health"},{"name":"German Federal Institute for Drugs and Medical Devices"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Ivabradine has been approved for the treatment of chronic heart failure and chronic stable angina pectoris in Europe. Based on adverse outcomes of reproductive animal studies and the lack of human data, ivabradine is considered contraindicated during pregnancy. The aim of this observational study is to analyse ivabradine use before and during pregnancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated all ivabradine-related requests to the German Embryotox Institute from 2007 to 2019. Exposed pregnancies were analysed as to their outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Off-label use for supraventricular tachycardia was frequent in women of childbearing age. Of 38 prospectively ascertained pregnancies with ivabradine exposure and completed follow-up, 32 resulted in live births, 3 in spontaneous abortions, and 3 were electively terminated. One neonate presented with major birth defects (atrial septal defect and cleft palate). In 33\/38 patients, ivabradine was discontinued after confirmation of pregnancy without cardiac deterioration and 5\/38 women continued ivabradine throughout pregnancy. In addition, there were 3 retrospectively reported pregnancies including one major birth defect (tracheal atresia).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case series represents the largest cohort of ivabradine-exposed pregnancies, published so far. According to our findings, ivabradine appears not to be a major teratogen. However, established drugs of choice with strong evidence of low risk for the unborn should be preferred in women planning pregnancy. After inadvertent exposure during pregnancy or lack of treatment alternatives, fetal ultrasound for structural anomalies and growth restriction is recommended. In addition, close monitoring is necessary in pregnant women with supraventricular arrhythmias or cardiac disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-020-03066-w","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T20:02:10Z","timestamp":1611691330000},"page":"1029-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ivabradine use in pregnant women\u2014treatment indications and pregnancy outcome: an evaluation of the German Embryotox database"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-4247","authenticated-orcid":false,"given":"Maria","family":"Hoeltzenbein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Louise","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-8563","authenticated-orcid":false,"given":"Evelin","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8674-5817","authenticated-orcid":false,"given":"Katarina","family":"Dathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9001-0525","authenticated-orcid":false,"given":"Christof","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"3066_CR1","unstructured":"EMA, Committee for Medicinal Products for Human Use (CHMP) (2011) Summary of opinion: Procoralan. Ivabradine. Accessed 8.9.2020 from https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-positive-summmary-opinion-procoralan_en.pdf"},{"key":"3066_CR2","unstructured":"FDA (2015) Pharmacology review(s). Accessed 8.9.2020 from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206143Orig1s000PharmR.pdf"},{"issue":"8","key":"3066_CR3","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/jcb.24527","volume":"114","author":"P Wang","year":"2013","unstructured":"Wang P, Tang M, Gao L, Luo H, Wang G, Ma X, Duan Y (2013) Roles of I(f) and intracellular Ca2+ release in spontaneous activity of ventricular cardiomyocytes during murine embryonic development. J Cell Biochem 114(8):1852\u20131862. https:\/\/doi.org\/10.1002\/jcb.24527","journal-title":"J Cell Biochem"},{"issue":"6","key":"3066_CR4","doi-asserted-by":"publisher","first-page":"H895","DOI":"10.1152\/ajpheart.00679.2012","volume":"304","author":"R Kockova","year":"2013","unstructured":"Kockova R, Svatunkova J, Novotny J, Hejnova L, Ostadal B, Sedmera D (2013) Heart rate changes mediate the embryotoxic effect of antiarrhythmic drugs in the chick embryo. Am J Physiol Heart Circ Physiol 304(6):H895\u2013H902. https:\/\/doi.org\/10.1152\/ajpheart.00679.2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"34","key":"3066_CR5","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","volume":"39","author":"V Regitz-Zagrosek","year":"2018","unstructured":"Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, GMC R, Seeland U, Simoncini T, Swan L, Warnes CA, Group ESCSD (2018) 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 39(34):3165\u20133241. https:\/\/doi.org\/10.1093\/eurheartj\/ehy340","journal-title":"Eur Heart J"},{"issue":"4","key":"3066_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ccd.22813","volume":"77","author":"Z Babic","year":"2011","unstructured":"Babic Z, Gabric ID, Pintaric H (2011) Successful primary percutaneous coronary intervention in the first trimester of pregnancy. Catheter Cardiovasc Interv 77(4):522\u2013525. https:\/\/doi.org\/10.1002\/ccd.22813","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"3066_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.14744\/AnatolJCardiol.2016.6813","volume":"16","author":"S Sag","year":"2016","unstructured":"Sag S, Coskun H, Baran I, Gullulu S, Aydinlar A (2016) Inappropriate sinus tachycardia-induced cardiomyopathy during pregnancy and successful treatment with ivabradine. Anatol J Cardiol 16(3):212\u2013213. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2016.6813","journal-title":"Anatol J Cardiol"},{"issue":"12","key":"3066_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00228-011-1085-5","volume":"67","author":"KT Lappegard","year":"2011","unstructured":"Lappegard KT, Nordmo E (2011) Ivabradine and nightmares: a previously unreported adverse reaction. Eur J Clin Pharmacol 67(12):1313\u20131314. https:\/\/doi.org\/10.1007\/s00228-011-1085-5","journal-title":"Eur J Clin Pharmacol"},{"key":"3066_CR9","unstructured":"EUROCAT (2019) European surveillance of congenital anomalies: Malformation Coding Guides. Accessed 8.9.2020 from http:\/\/www.eurocat-network.eu\/aboutus\/datacollection\/guidelinesforregistration\/malformationcodingguides"},{"issue":"1","key":"3066_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","volume":"26","author":"C Schaefer","year":"2008","unstructured":"Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C (2008) Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. Reprod Toxicol 26(1):36\u201341. https:\/\/doi.org\/10.1016\/j.reprotox.2008.05.064","journal-title":"Reprod Toxicol"},{"issue":"2","key":"3066_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00228-017-2351-y","volume":"74","author":"K Dathe","year":"2018","unstructured":"Dathe K, Schaefer C (2018) Drug safety in pregnancy: the German Embryotox institute. Eur J Clin Pharmacol 74(2):171\u2013179. https:\/\/doi.org\/10.1007\/s00228-017-2351-y","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3066_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1055\/s-0034-1385857","volume":"218","author":"M Voigt","year":"2014","unstructured":"Voigt M, Rochow N, Schneider KT, Hagenah HP, Scholz R, Hesse V, Wittwer-Backofen U, Straube S, Olbertz D (2014) New percentile values for the anthropometric dimensions of singleton neonates: analysis of perinatal survey data of 2007-2011 from all 16 states of Germany. Z Geburtshilfe Neonatol 218(5):210\u2013217. https:\/\/doi.org\/10.1055\/s-0034-1385857","journal-title":"Z Geburtshilfe Neonatol"},{"issue":"6","key":"3066_CR13","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","volume":"12","author":"RS Sheldon","year":"2015","unstructured":"Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA, Moak JP, Sandhu RK, Kanjwal K (2015) 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 12(6):e41\u2013e63. https:\/\/doi.org\/10.1016\/j.hrthm.2015.03.029","journal-title":"Heart Rhythm"},{"issue":"13","key":"3066_CR14","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.jacc.2015.08.856","volume":"67","author":"RL Page","year":"2016","unstructured":"Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NAM 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM (2016) 2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 67(13):e27\u2013e115. https:\/\/doi.org\/10.1016\/j.jacc.2015.08.856","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3066_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"J Brugada","year":"2020","unstructured":"Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, Calkins H, Corrado D, Deftereos SG, Diller GP, Gomez-Doblas JJ, Gorenek B, Grace A, Ho SY, Kaski JC, Kuck KH, Lambiase PD, Sacher F, Sarquella-Brugada G, Suwalski P, Zaza A, Group ESCSD (2020) 2019 ESC guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 41(5):655\u2013720. https:\/\/doi.org\/10.1093\/eurheartj\/ehz467","journal-title":"Eur Heart J"},{"issue":"5","key":"3066_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/bdr2.1457","volume":"111","author":"HE Ritchie","year":"2019","unstructured":"Ritchie HE, Telenius C, Gustaffson E, Webster WS (2019) The effects of nifedipine and ivabradine on the functionality of the early rat embryonic heart. Are these drugs a risk in early human pregnancy? Birth Defects Res 111(5):281\u2013288. https:\/\/doi.org\/10.1002\/bdr2.1457","journal-title":"Birth Defects Res"},{"issue":"4","key":"3066_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s12687-018-0384-2","volume":"9","author":"S Moorthie","year":"2018","unstructured":"Moorthie S, Blencowe H, Darlison MW, Lawn J, Morris JK, Modell B, Bittles AH, Blencowe H, Christianson A, Cousens S, Darlison MW, Gibbons S, Hamamy H, Khoshnood B, Howson CP, Lawn J, Mastroiacovo P, Modell B, Moorthie S, Morris JK, Mossey PA, Neville AJ, Petrou M, Povey S, Rankin J, Schuler-Faccini L, Wren C, Yunnis KA (2018) Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. J Community Genet 9(4):387\u2013396. https:\/\/doi.org\/10.1007\/s12687-018-0384-2","journal-title":"J Community Genet"},{"key":"3066_CR18","unstructured":"EUROCAT (2019) European surveillance of congenital, anomalies: Prevalence Tables. Accessed 8.9.2020 from http:\/\/www.eurocat-network.eu\/accessprevalencedata\/prevalencetable"},{"issue":"4","key":"3066_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.bpobgyn.2011.01.006","volume":"25","author":"JA Hutcheon","year":"2011","unstructured":"Hutcheon JA, Lisonkova S, Joseph KS (2011) Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 25(4):391\u2013403. https:\/\/doi.org\/10.1016\/j.bpobgyn.2011.01.006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"3066_CR20","doi-asserted-by":"publisher","unstructured":"Kugamoorthy P, Spears DA (2020) Management of tachyarrhythmias in pregnancy - a review. Obstetric Medicine: 1753495X20913448. https:\/\/doi.org\/10.1177\/1753495X20913448","DOI":"10.1177\/1753495X20913448"},{"issue":"2","key":"3066_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.hrthm.2017.10.004","volume":"15","author":"ST Mathew","year":"2018","unstructured":"Mathew ST, Po SS, Thadani U (2018) Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: a pooled analysis of prospective studies. Heart Rhythm 15(2):240\u2013247. https:\/\/doi.org\/10.1016\/j.hrthm.2017.10.004","journal-title":"Heart Rhythm"},{"issue":"4","key":"3066_CR22","doi-asserted-by":"publisher","first-page":"e227789","DOI":"10.1136\/bcr-2018-227789","volume":"12","author":"MA Cheema","year":"2019","unstructured":"Cheema MA, Zain MA, Ullah W, Cheema K (2019) Is ivabradine a wonder drug for atypical POTS? BMJ Case Rep 12(4):e227789. https:\/\/doi.org\/10.1136\/bcr-2018-227789","journal-title":"BMJ Case Rep"},{"issue":"7","key":"3066_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/pace.12118","volume":"36","author":"J Benezet-Mazuecos","year":"2013","unstructured":"Benezet-Mazuecos J, Rubio JM, Farre J, Quinones MA, Sanchez-Borque P, Macia E (2013) Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol 36(7):830\u2013836. https:\/\/doi.org\/10.1111\/pace.12118","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"3066_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10840-015-0066-5","volume":"46","author":"M Annamaria","year":"2016","unstructured":"Annamaria M, Lupo PP, Foresti S, De Ambroggi G, de Ruvo E, Sciarra L, Cappato R, Calo L (2016) Treatment of inappropriate sinus tachycardia with ivabradine. J Interv Card Electrophysiol 46(1):47\u201353. https:\/\/doi.org\/10.1007\/s10840-015-0066-5","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"3066_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/jce.14288","volume":"31","author":"SA Shabtaie","year":"2020","unstructured":"Shabtaie SA, Witt CM, Asirvatham SJ (2020) Natural history and clinical outcomes of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol 31(1):137\u2013143. https:\/\/doi.org\/10.1111\/jce.14288","journal-title":"J Cardiovasc Electrophysiol"},{"key":"3066_CR26","doi-asserted-by":"publisher","unstructured":"Belham M, Patient C, Pickett J (2017) Inappropriate sinus tachycardia in pregnancy: a benign phenomena? BMJ Case Rep 2017. https:\/\/doi.org\/10.1136\/bcr-2016-217026","DOI":"10.1136\/bcr-2016-217026"},{"issue":"5","key":"3066_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.bpobgyn.2015.04.002","volume":"29","author":"Y Emmanuel","year":"2015","unstructured":"Emmanuel Y, Thorne SA (2015) Heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol 29(5):579\u2013597. https:\/\/doi.org\/10.1016\/j.bpobgyn.2015.04.002","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"9","key":"3066_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMsa1506575","volume":"374","author":"LB Finer","year":"2016","unstructured":"Finer LB, Zolna MR (2016) Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med 374(9):843\u2013852. https:\/\/doi.org\/10.1056\/NEJMsa1506575","journal-title":"N Engl J Med"},{"issue":"2","key":"3066_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.hrthm.2019.08.004","volume":"17","author":"TM Roston","year":"2020","unstructured":"Roston TM, van der Werf C, Cheung CC, Grewal J, Davies B, Wilde AAM, Krahn AD (2020) Caring for the pregnant woman with an inherited arrhythmia syndrome. Heart Rhythm 17(2):341\u2013348. https:\/\/doi.org\/10.1016\/j.hrthm.2019.08.004","journal-title":"Heart Rhythm"},{"key":"3066_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.reprotox.2016.11.019","volume":"67","author":"E Beck","year":"2017","unstructured":"Beck E, Lechner A, Schaefer C (2017) Who seeks Teratology Information Service\u2019s advice? Assessing the risk of selection bias in observational cohort studies on drug risks in pregnancy. Reprod Toxicol 67:79\u201384. https:\/\/doi.org\/10.1016\/j.reprotox.2016.11.019","journal-title":"Reprod Toxicol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03066-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03066-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03066-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:16:58Z","timestamp":1623068218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03066-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3066"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03066-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"assertion":[{"value":"27 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was registered with the German Clinical Trial register (DRKS00010502) and the study protocol was approved by the ethics committee of the Charit\u00e9-Universit\u00e4tsmedizin Berlin (EA1\/107\/16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}